BioMarin to acquire Alesta Therapeutics for $275 million upfront plus milestone payments
BioMarin agreed on August 17, 2026 to acquire Alesta Therapeutics, a Dutch clinical-stage biotech, for a $275 million upfront cash payment plus up to $215 million in future payments tied to development milestones. Alesta will first spin out its non-ALE1 assets, and BioMarin expects to fund the deal with cash on hand and to update its full-year 2026 guidance after closing; the company says the deal is expected to be modestly dilutive to 2026 results excluding the upfront payment.
Key points
- Upfront cash payment of $275 million, subject to a customary post-closing price adjustment, plus up to $215 million in milestone-based payments
- Lead asset ALE1 is an oral small molecule in a Phase 1/2a trial for hypophosphatasia, a rare genetic bone disease
- Closing expected in the third quarter of 2026, subject to closing conditions; BioMarin plans to fund the deal with cash on hand
- Filing states the deal is expected to be modestly dilutive to 2026 results, excluding the upfront consideration
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.